GW prepares for 2018 US launch of epilepsy drug

07:54 EDT 8 Aug 2017 | pharmaphorum

GW Pharmaceuticals has said it is preparing to launch its cannabis-based childhood epilepsy drug in the US next year, as biotech Zynerba assesses the fallout from a failed phase 2 trial of a cannabis drug in adult disease. GW is developing Epidiol...

Original Article: GW prepares for 2018 US launch of epilepsy drug


More From BioPortfolio on "GW prepares for 2018 US launch of epilepsy drug"

Quick Search

Relevant Topics

Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...